Zoetis Inc. (/zō-EH-tis/) is an American drug company, the world's largest producer of medicine and vaccinations for pets and livestock. The company was a subsidiary of Pfizer, the world's largest drug maker, but with Pfizer's spinoff of its 83% interest in the firm it is now a completely independent company. The company directly markets its products in approximately 45 countries, and sells them in more than 100 countries. Operations outside the United States accounted for 50% of the total revenue. Contemporaneous with the spinoff in June 2013 S&P Dow Jones Indices announced that Zoetis would replace First Horizon National Corporation in the S&P 500 stock market index.
| trading_symbol | registrant_name | time | price | change | percentage_change |
|---|---|---|---|---|---|
| ZTS | Zoetis Inc. | 2026-02-17 23:29:52 | 125.75 | 0.19 | 0.15 |
| trading_symbol | central_index_key | registrant_name | isin_number | lei_number | ein_number | exchange | sic_code | sic_description | fiscal_year_end | state_of_incorporation | address_street | address_city | address_state | address_zip_code | address_country | address_country_code | phone_number | mailing_address | business_address | former_name | industry | founding_date | chief_executive_officer | number_of_employees | website | market_cap | shares_issued | shares_outstanding | description | update_time |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ZTS | 0001555280 | Zoetis Inc. | US98978V1035 | 549300HD9Q1LOC9KLJ48 | 460696167 | NYSE | 2834 | Pharmaceutical Preparations | 1231 | — | 10 SYLVAN WAY | PARSIPPANY | NJ | 07054 | UNITED STATES | US | 973-822-7000 | 10 SYLVAN WAY, PARSIPPANY, NJ, 07054 | 10 SYLVAN WAY, PARSIPPANY, NJ, 07054 | — | Pharmaceutical | 1952 | Kristin Peck | 13,800 | http://zoetis.com | 78,673,000,000 | 501,891,243 | 440,693,214 | Zoetis Inc. (/zō-EH-tis/) is an American drug company, the world's largest producer of medicine and vaccinations for pets and livestock. The company was a subsidiary of Pfizer, the world's largest drug maker, but with Pfizer's spinoff of its 83% interest in the firm it is now a completely independent company. The company directly markets its products in approximately 45 countries, and sells them in more than 100 countries. Operations outside the United States accounted for 50% of the total revenue. Contemporaneous with the spinoff in June 2013 S&P Dow Jones Indices announced that Zoetis would replace First Horizon National Corporation in the S&P 500 stock market index. | 2026-02-12 15:24:11 |
| Fiscal Year | Market Cap | Change In Market Cap | Percentage Change In Market Cap | Shares Outstanding | Change In Shares Outstanding | Percentage Change In Shares Outstanding |
|---|---|---|---|---|---|---|
| 2025 | 69,233,000,000 | -9,440,000,000 | -11.999 | 422,127,709 | -25,664,208 | -5.7313 |
| 2024 | 78,673,000,000 | -673,000,000 | -0.8482 | 447,791,917 | -10,075,198 | -2.2005 |
| 2023 | 79,346,000,000 | -1,204,000,000 | -1.4947 | 457,867,115 | -5,519,601 | -1.1911 |
| Executive Name | Executive Position | Fiscal Year | Salary | Bonus | Stock Awards | Incentive Plan Compensation | Other Compensation | Total Compensation |
|---|---|---|---|---|---|---|---|---|
| Kristin C. Peck | Chief Executive Officer | 2021 | 1,200,000 | 0 | 6,929,797 | 2,340,000 | 318,724 | 13,098,491 |
| Catherine A. Knupp | EVP, President | 2021 | 710,000 | 0 | 1,368,661 | 852,000 | 168,376 | 3,555,260 |
| Roman Trawicki | EVP, President | 2021 | 675,000 | 0 | 1,049,922 | 842,400 | 401,419 | 3,318,727 |
| Heidi C. Chen | EVP, Corporate Secretary, General Counsel | 2021 | 615,000 | 0 | 993,543 | 645,750 | 133,861 | 2,719,382 |
| Catherine A. Knupp | EVP, President | 2020 | 710,000 | 0 | 1,349,924 | 658,880 | 137,097 | 3,305,884 |
| Fiscal Year | Employee Count |
|---|---|
| 2025 | 14,500 |
| 2024 | 13,800 |
| 2023 | 14,100 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Revenue | 9,467,000,000 | 9,256,000,000 | 8,544,000,000 |
| Cost Of Revenue | 2,666,000,000 | 2,719,000,000 | 2,561,000,000 |
| Gross Profit | 4,255,000,000 | 4,138,000,000 | 3,655,000,000 |
| Research And Development Expenses | 698,000,000 | 686,000,000 | 614,000,000 |
| General And Administrative Expenses | 2,378,000,000 | 2,318,000,000 | 2,151,000,000 |
| Operating Expenses | 817,000,000 | 805,000,000 | 786,000,000 |
| Operating Income | — | — | — |
| Net Income | 2,673,000,000 | 2,486,000,000 | 2,344,000,000 |
| Earnings Per Share Basic | 6.03 | 5.47 | 5.08 |
| Earnings Per Share Diluted | 6.02 | 5.47 | 5.07 |
| Weighted Average Shares Outstanding Basic | 443,443,000 | 454,200,000 | 461,172,000 |
| Weighted Average Shares Outstanding Diluted | 443,835,000 | 454,848,000 | 462,269,000 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Cash And Cash Equivalents | 2,312,000,000 | 1,987,000,000 | 2,041,000,000 |
| Marketable Securities Current | — | — | — |
| Accounts Receivable | 1,590,000,000 | 1,316,000,000 | 1,304,000,000 |
| Inventories | 2,430,000,000 | 2,306,000,000 | 2,564,000,000 |
| Non Trade Receivables | — | — | — |
| Other Assets Current | 436,000,000 | 377,000,000 | 434,000,000 |
| Total Assets Current | 6,768,000,000 | 5,986,000,000 | 6,343,000,000 |
| Marketable Securities Non Current | — | — | — |
| Property Plant And Equipment | 3,681,000,000 | 3,391,000,000 | 3,204,000,000 |
| Other Assets Non Current | 328,000,000 | 250,000,000 | 206,000,000 |
| Total Assets Non Current | 8,699,000,000 | 8,251,000,000 | 7,943,000,000 |
| Total Assets | 15,467,000,000 | 14,237,000,000 | 14,286,000,000 |
| Accounts Payable | 487,000,000 | 433,000,000 | 411,000,000 |
| Deferred Revenue | — | — | — |
| Short Term Debt | 0 | 0 | 3,000,000 |
| Other Liabilities Current | 107,000,000 | 125,000,000 | 102,000,000 |
| Total Liabilities Current | 2,235,000,000 | 3,412,000,000 | 1,889,000,000 |
| Long Term Debt | 9,042,000,000 | 5,220,000,000 | 6,564,000,000 |
| Other Liabilities Non Current | 248,000,000 | 222,000,000 | 237,000,000 |
| Total Liabilities Non Current | 9,901,000,000 | 6,055,000,000 | 7,406,000,000 |
| Total Liabilities | 12,136,000,000 | 9,467,000,000 | 9,295,000,000 |
| Common Stock | 5,000,000 | 5,000,000 | 5,000,000 |
| Retained Earnings | 13,744,000,000 | 11,968,000,000 | 10,295,000,000 |
| Accumulated Other Comprehensive Income | -834,000,000 | -940,000,000 | -839,000,000 |
| Total Shareholders Equity | 3,331,000,000 | 4,770,000,000 | 4,997,000,000 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Depreciation And Amortization | 487,000,000 | 497,000,000 | 491,000,000 |
| Share Based Compensation Expense | 83,000,000 | 74,000,000 | 60,000,000 |
| Other Non Cash Income Expense | 8,000,000 | 6,000,000 | 8,000,000 |
| Change In Accounts Receivable | 236,000,000 | 61,000,000 | 102,000,000 |
| Change In Inventories | 199,000,000 | 40,000,000 | 361,000,000 |
| Change In Non Trade Receivables | — | — | — |
| Change In Other Assets | 165,000,000 | -52,000,000 | 95,000,000 |
| Change In Accounts Payable | 46,000,000 | 31,000,000 | 13,000,000 |
| Change In Other Liabilities | 85,000,000 | 114,000,000 | 67,000,000 |
| Cash From Operating Activities | 2,904,000,000 | 2,953,000,000 | 2,353,000,000 |
| Purchases Of Marketable Securities | 7,000,000 | 5,000,000 | 4,000,000 |
| Sales Of Marketable Securities | — | — | — |
| Acquisition Of Property Plant And Equipment | 621,000,000 | 655,000,000 | 732,000,000 |
| Acquisition Of Business | — | — | — |
| Other Investing Activities | -1,000,000 | 3,000,000 | -2,000,000 |
| Cash From Investing Activities | -748,000,000 | -315,000,000 | -777,000,000 |
| Tax Withholding For Share Based Compensation | — | — | — |
| Payments Of Dividends | 897,000,000 | 812,000,000 | 716,000,000 |
| Issuance Of Common Stock | — | — | — |
| Repurchase Of Common Stock | 3,235,000,000 | 1,858,000,000 | 1,092,000,000 |
| Issuance Of Long Term Debt | 1,848,000,000 | 0 | 0 |
| Repayment Of Long Term Debt | 1,350,000,000 | 0 | 1,350,000,000 |
| Other Financing Activities | -3,000,000 | — | — |
| Cash From Financing Activities | -1,870,000,000 | -2,660,000,000 | -3,109,000,000 |
| Change In Cash | 325,000,000 | -54,000,000 | -1,540,000,000 |
| Cash At End Of Period | 2,312,000,000 | 1,987,000,000 | 2,041,000,000 |
| Income Taxes Paid | 715,000,000 | 892,000,000 | 754,000,000 |
| Interest Paid | 261,000,000 | 274,000,000 | 295,000,000 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Earnings Per Share | 6.03 | 5.47 | 5.08 |
| Price To Earnings Ratio | 20.8657 | 29.7861 | 38.8524 |
| Earnings Growth Rate | 10.2377 | 7.6772 | 12.6386 |
| Price Earnings To Growth Ratio | 2.0381 | 3.8798 | 3.0741 |
| Book Value Per Share | 7.5117 | 10.502 | 10.8224 |
| Price To Book Ratio | 16.7499 | 15.5142 | 18.2371 |
| Ebitda | 4,097,000,000 | 4,100,000,000 | 3,828,000,000 |
| Enterprise Value | 62,523,998,260 | 77,235,806,000 | 95,547,517,640 |
| Dividend Yield | 0.0161 | 0.011 | 0.0079 |
| Dividend Payout Ratio | 0.3356 | 0.3266 | 0.3055 |
| Debt To Equity Ratio | 2.7145 | 1.0943 | 1.3142 |
| Capital Expenditures | 777,000,000 | 684,000,000 | 942,000,000 |
| Free Cash Flow | 2,127,000,000 | 2,269,000,000 | 1,411,000,000 |
| Return On Equity | 0.8025 | 0.5212 | 0.4691 |
| One Year Beta | 0.6187 | 0.6237 | 1.0077 |
| Three Year Beta | 0.7133 | 0.9172 | 0.9525 |
| Five Year Beta | 0.8293 | 0.9215 | 0.9436 |
| Insider Name | Relationship To Issuer | Transaction Date | Amount Of Securities | Acquired Or Disposed | Securities Owned Following Transaction |
|---|---|---|---|---|---|
| PECK KRISTIN C | Director, Chief Executive Officer | 2026-02-17 | 20,000 | A | 121,337 |
| PECK KRISTIN C | Director, Chief Executive Officer | 2026-02-17 | 9,200 | D | 112,137 |
| PECK KRISTIN C | Director, Chief Executive Officer | 2026-02-17 | 10,800 | D | 101,337 |
| PECK KRISTIN C | Director, Chief Executive Officer | 2026-02-17 | 20,000 | D | 249,632 |
| PECK KRISTIN C | Director, Chief Executive Officer | 2026-02-08 | 6,224 | A | 104,059 |
| Name Of Reporting Person | Type Of Reporting Person | Report Date | Transaction Type | Transaction Date | Owner Type | Amount |
|---|---|---|---|---|---|---|
| Markwayne Mullin | Senator | 2025-12-05 | Sale (Full) | 2025-11-10 | Joint | $15,001 - $50,000 |
| Markwayne Mullin | Senator | 2025-08-12 | Purchase | 2024-01-04 | Self | $1,001 - $15,000 |
| Markwayne Mullin | Senator | 2025-08-12 | Purchase | 2024-01-04 | Spouse | $1,001 - $15,000 |
| Markwayne Mullin | Senator | 2025-06-11 | Purchase | 2025-05-13 | Joint | $50,001 - $100,000 |
| Markwayne Mullin | Senator | 2025-05-12 | Sale (Full) | 2025-04-08 | Joint | $15,001 - $50,000 |
| Name Of Reporting Person | Report Date | State | Transaction Type | Transaction Date | Owner Type | Amount |
|---|---|---|---|---|---|---|
| Gilbert Cisneros | 2026-01-12 | CA31 | Purchase | 2025-12-19 | — | $1,001 - $15,000 |
| Gilbert Cisneros | 2025-12-15 | CA31 | Purchase | 2025-11-18 | — | $1,001 - $15,000 |
| Rick Larsen | 2025-10-16 | WA02 | Sale | 2025-10-06 | — | $1,001 - $15,000 |
| Gilbert Cisneros | 2025-09-12 | CA31 | Sale (Partial) | 2025-08-05 | — | $1,001 - $15,000 |
| Lisa McClain | 2025-09-12 | MI09 | Sale | 2025-08-04 | Spouse | $1,001 - $15,000 |
| Investor Name | Period Of Report | Market Value | Amount Of Securities | Price Per Security |
|---|---|---|---|---|
| GAM Holding AG | 2025-12-31 | 1,057,140 | 8,402 | 125.82 |
| LAZARD ASSET MANAGEMENT LLC | 2025-12-31 | 134,963,927 | 1,072,675 | 125.82 |
| Cetera Investment Advisers | 2025-12-31 | 11,299,201 | 89,804 | 125.8207 |
| Freestone Grove Partners LP | 2025-12-31 | 4,060,337 | 32,271 | 125.82 |
| GUGGENHEIM CAPITAL LLC | 2025-12-31 | 42,562,137 | 338,278 | 125.82 |
| Registrant Name | Period Of Report | Fund Name | Fund Symbol | Amount Of Units | Value In Usd | Percentage Value Compared To Assets |
|---|---|---|---|---|---|---|
| EMPOWER FUNDS, INC. | 2025-12-31 | Institutional Class | MXUGX | 112,000 | 115,080 | 0.0083 |
| EMPOWER FUNDS, INC. | 2025-12-31 | Investor Class | MXLMX | 112,000 | 115,080 | 0.0083 |
| EMPOWER FUNDS, INC. | 2025-12-31 | Institutional Class | MXKWX | 70,660 | 8,890,441.12 | 0.0962 |
| EMPOWER FUNDS, INC. | 2025-12-31 | Investor Class | MXVIX | 70,660 | 8,890,441.12 | 0.0962 |
| EMPOWER FUNDS, INC. | 2025-12-31 | Institutional Class | MXCOX | 1,000,000 | 914,873.13 | 0.0191 |